Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2024 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
February 02, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of January 29, 2024, the...
January 17, 2024 16:01 ET | Source: Vor Biopharma

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
December 21, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of December 20, 2023, the...
December 01, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the...
November 27, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
November 09, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
November 07, 2023 16:05 ET | Source: Vor Biopharma

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
November 03, 2023 16:01 ET | Source: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the...
November 03, 2023 08:00 ET | Source: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...